KMDA: צמיחת הכנסות רבעונית Kamada Ltd.

Stable cash flow from government contracts and global sales of biologics supports the R&D activity of Kamada Ltd. (KMDA). Quarterly revenue changes visualize the pace of fund generation, where 10.80 serves as the current parameter value. Growth is driven by contracts with Takeda and expansion in the US, although business success relies on plasma availability and the efficacy of new treatments for genetic pathologies.
פילוחי נתונים אנליטיים מרוכזים עבור Kamada Ltd (KMDA)

Kamada Ltd. manages a complex plasma processing infrastructure in Israel and logistics in the US. This metric measures the percentage change in sales volume for the current quarter relative to the previous one, identifying short-term demand trends. For the investor, this serves as an indicator of operational efficiency and the stability of biopharmaceutical supplies. By analyzing the QoQ revenue growth rate, one can determine the market cycle phase and the risk of cooling demand.